Evaluation of the use of 68Ga-peptide somatostatin analogue PET/CT as a diagnostic tool in neuroendocrine tumors and its correlation with molecular markers

• Grant number: 13/03876-4
• Support Opportunities: Regular Research Grants
• Start date: June 01, 2013
• End date: November 30, 2015
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Ana Amélia Fialho de Oliveira Hoff
• Grantee: Ana Amélia Fialho de Oliveira Hoff
• Host Institution: Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira (ICESP). Coordenadoria de Serviços de Saúde (CSS). Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil
• Associated researchers: Antonio Marcondes Lerario ; Carlos Alberto Buchpiguel ; Delmar Muniz Lourenço Jr ; Ericka Barbosa Trarbach ; George Barberio Coura Filho ; Marcello Delano Bronstein ; Marcelo Tatit Sapienza ; Maria Adelaide Albergaria Pereira ; Maria Candida Barisson Villares Fragoso ; Rachel Simões Pimenta Riechelmann ; Renata de Almeida Coudry ; Rui Monteiro de Barros Maciel ; Tulio Eduardo Flesch Pfiffer

Abstract

Despite recent therapeutic advances, surgical resection remains the only curative treatment for neuroendocrine tumors; therefore the development of more sensitive diagnostic tools that allows earlier detection of disease is highly desirable. The currently used localization studies include ultrasonography (US), computed tomography (CT), magnetic resonance imaging (MRI) and octreoscan; the latter is a functional study based on the property of these tumors to express somatostatin receptors. The high resolution PET/CT with deoxiglucose marked with 18F (18FDG PET/CT) is useful for tumors with aggressive behavior and high glucose consumption. The studies investigating the role of 18FDG PET/CT in neuroendocrine tumors have demonstrated a high sensitivity only with the high-grade tumors, however most of the neuroendocrine tumors have an indolent behavior. The recent development of PET/CT with somatostatin analogs marked with 68Galium allows the association of a high sensitivity structural imaging study with the specificity of a functional study. Recent studies that investigated well-differentiated and moderately-differentiated neuroendocrine tumors have shown the superiority of this tool in comparison to the available imaging studies. The primary goal of this study is to evaluate the efficacy of 68Ga-SOMATOSTATIN ANALOG PET/CT in different types of neuroendocrine tumors, and the secondary goals include the correlation of imaging findings with the proliferative index Ki-67 and with the gene and protein expression of the somatostatin receptors, and the analysis of micro RNAS which are known to regulate expression of these receptors. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

JOSEFSSON, ANDERS; HOBBS, ROBERT F.; RANKA, SAGAR; SCHWARZ, BRYAN C.; PLYKU, DONIKA; DE AMORIM DE CARVALHO, JOSE WILLEGAIGNON; BUCHPIGUEL, CARLOS ALBERTO; SAPIENZA, MARCELO TATIT; BOLCH, WESLEY E.; SGOUROS, GEORGE. Comparative Dosimetry for Ga-68-DOTATATE: Impact of Using Updated ICRP Phantoms, S Values, and Tissue-Weighting Factors. JOURNAL OF NUCLEAR MEDICINE, v. 59, n. 8, p. 1281-1288, AUG 1 2018. (13/03876-4)

CASTRONEVES, LUCIANA AUDI; COURA FILHO, GEORGE; COSTA DE FREITAS, RICARDO MIGUEL; SALLES, RAPHAEL; MOYSES, RAQUEL AJUB; MENDOZA LOPEZ, ROSSANA VERONICA; ALBERGARIA PEREIRA, MARIA ADELAIDE; TAVARES, MARCOS ROBERTO; DE LIMA JORGE, ALEXANDER AUGUSTO; BUCHPIGUEL, CARLOS ALBERTO; et al. Comparison of Ga-68 PET/CT to Other Imaging Studies in Medullary Thyroid Cancer: Superiority in Detecting Bone Metastases. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, v. 103, n. 9, p. 3250-3259, SEP 2018. (13/03876-4)

JOSEFSSON, ANDERS; SIRITANTIKORN, KLAIKANGWOL; RANKA, SAGAR; DE CARVALHO, JOSE WILLEGAIGNON DE AMORIM; BUCHPIGUEL, CARLOS ALBERTO; SAPIENZA, MARCELO TATIT; BOLCH, WESLEY E.; SGOUROS, GEORGE. Accuracy in dosimetry of diagnostic agents: impact of the number of source tissues used in whole organ S value-based calculations. EJNMMI RESEARCH, v. 10, n. 1, MAR 19 2020. (13/03876-4)